Haverford Trust Co Makes New Investment in Bristol Myers Squibb Company $BMY

23 Aug 2026, 13:12 by Michael Walen · The Markets Daily

Haverford Trust Co purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 40,920 shares of the biopharmaceutical company’s stock, valued at approximately $2,358,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $27,000. Finally, Bayban purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $31,000. 76.41% of the stock is owned by institutional investors and hedge funds.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Bristol Myers Squibb Stock Up 2.4%

BMY stock opened at $67.06 on Friday. The stock has a market cap of $136.98 billion, a P/E ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company’s 50 day moving average is $60.55 and its two-hundred day moving average is $59.37.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent analyst reports. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Roth Capital started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target on the stock. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Piper Sandler started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $66.06.

Read Our Latest Research Report on Bristol Myers Squibb

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.